Please Wait...

Arthritis

Clinical Assessment of Rheumatoid Arthritis: Advantage MRI

  • 0
  • 29 Aug

When designing imaging endpoints for prospective clinical trials in Rheumatoid Arthritis (RA), sponsors often consider the use of Magnetic Resonance Imaging (MRI) for assessment. The utilization of MRI enables the detection of soft tissues for synovial and bone marrow findings in addition to structural damage, providing advanced evaluation of RA.

Read More
Anti Nerve Growth Factor

Monitoring the Joint Safety of Anti-Nerve Growth Factor Drugs

  • 0
  • 25 Jul

The March 12, 2012 meeting of the Arthritis Advisory Committee (AAC) of the Food and Drug Administration (FDA) focused on the safety of the anti-nerve growth factor (anti-NGF) drug class. Anti-NGF agents are being developed primarily for the treatment of chronic pain associated with osteoarthritis (OA).

There are three anti-nerve growth factor monoclonal antibodies in clinical development including:

  • Tanezumab (Pfizer) in phase III
  • Fulranumab (Janssen) in phase II
  • REGN475 (Regeneron) in phase II
Read More

MRI in Rheumatoid Arthritis Clinical Trials

  • 0
  • 13 Jan

At BioClinica we are fortunate to have a medical affairs group staffed with a medically and scientifically qualified team whose role is to help sponsors with imaging protocol design and how to use emerging technologies to our advantage. Harris Ahmad, M.D.

Read More

LEARN MORE OR SPEAK WITH OUR EXPERTS

CONTACT US
Leader in Clinical Trial
Management Solutions

Bioclinica is organized into three business segments so that we can provide expert service and multifaceted technologies. Our Medical Imaging & Biomarkers segment includes an Imaging Core Lab, a Cardiovascular Safety division, and a Molecular Marker Laboratory. Our eHealth segment comprises eClinical Solutions, Randomization & Trial Supply Management, Safety & Regulatory Solutions, and Financial Lifecycle Solutions. Under the Global Clinical Research segment, we offer a network of research sites, patient recruitment, and a Post-Approval Research division.

RT @Xtalks: Removing Risk from #ClinicalTrial Management System (CTMS) Implementations @bioclinica https://t.co/EfuSVMSL13
bioclinica (5 hours ago)
Our Research Dev. Director Marieke Cajal in a poster presentation at #CNS Summit showed, "How to Scale up Recruitme… https://t.co/ySQpGIjvt9
bioclinica (5 hours ago)
Great advice on imaging in #clinicaltrials! https://t.co/adsP8h99Ic
bioclinica (3 days ago)
https://t.co/UZQTot9ovJ
bioclinica (3 days ago)
RT @Xtalks: When is Central Imaging Needed in #ClinicalTrials? @bioclinica https://t.co/fYGvqU46TI
bioclinica (3 days ago)
RT @phillytechnews: 11/7: BioClinica, USA Technologies buy California firms ; First Round names female general partner https://t.co/MAvm6…
bioclinica (3 days ago)

Latest Blogs:

Removing Risk from Clinical Trial Management System (CTMS) Implementations
Collaboration Between Clinical Operations and the Logistics and Supply Chain Teams is Key to Trial Success
The Value of Protocol Review
CTMS and RBM: Hot Topics at OCT Nordics in Copenhagen
Congressman Meehan and Bioclinica CEO John Hubbard at recent visit to Bioclinica's Audubon offices